Latest Pharmaceuticals News

Page 47 of 63
Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.
Ada Torres
Ada Torres
10 June 2025
Firebrick Pharma has unexpectedly withdrawn its planned share placement, raising questions about its capital strategy amid ongoing product launches.
Victor Sage
Victor Sage
6 June 2025
Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.
Ada Torres
Ada Torres
6 June 2025
Clarity Pharmaceuticals reports that its Cu-SARTATE diagnostic agent significantly outperforms the current standard in detecting neuroendocrine tumours, paving the way for a pivotal Phase III study.
Ada Torres
Ada Torres
5 June 2025
Mayne Pharma disputes Cosette Pharmaceuticals’ attempt to terminate their acquisition agreement, with a key court hearing postponed to September and a crucial shareholder vote set for June 18.
Victor Sage
Victor Sage
5 June 2025
Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ notice attempting to terminate their merger agreement, setting the stage for a potential courtroom showdown over the disputed deal.
Ada Torres
Ada Torres
4 June 2025
Mayne Pharma rebuffs Cosette's claim of a material adverse change in their merger scheme and secures FDA clearance on regulatory concerns, maintaining its commitment to the deal's completion.
Ada Torres
Ada Torres
4 June 2025
Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.
Ada Torres
Ada Torres
3 June 2025
Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.
Ada Torres
Ada Torres
2 June 2025
Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.
Ada Torres
Ada Torres
2 June 2025
EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.
Ada Torres
Ada Torres
2 June 2025
Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.
Ada Torres
Ada Torres
30 May 2025